|
4/23/15
|
AbbVie Reports First-Quarter 2015 Financial Results
- Reports First-Quarter Adjusted EPS of $0.94, Up 32.4 Percent and Exceeding Previous Guidance Range of $0.82 to $0.84 (Reports GAAP EPS of $0.63) - Delivers First-Quarter Revenue of $5.040 Billion, an Increase of 17.8 Percent Over First-Quarter 2014 on an Operational Basis (Up 10.5 Percent on a
|
|
|
4/17/15
|
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
NORTH CHICAGO, Ill. , April 17, 2015 /PRNewswire/ -- AbbVie Inc. (" AbbVie ") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m.
|
|
|
4/15/15
|
AbbVie to Host First-Quarter Earnings Conference Call
NORTH CHICAGO, Ill. , April 15, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2015 financial results on Thursday, April 23, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern).
|
|
|
3/6/15
|
AbbVie to Present at Barclays Global Health Care Conference
NORTH CHICAGO, Ill. , March 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Health Care Conference on Thursday, March 12, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and answer session at 8:30 a.m.
|
|
|
3/4/15
|
AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise
- Adds Imbruvica® a first in class BTK inhibitor approved in multiple indications for blood cancers. - Extensive clinical program with over 50 studies ongoing evaluating Imbruvica® as a treatment for a wide range of additional indications, including early assessments for solid tumors and potential
|
|
|
2/19/15
|
AbbVie Increases Quarterly Dividend
NORTH CHICAGO, Ill. , Feb. 19, 2015 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 4 percent from $0.49 per share to $0.51 per share. The cash dividend is payable May 15, 2015 to stockholders of record at the close of business
|
|
|
1/30/15
|
AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results
- Reports Full-Year Adjusted EPS of $3.32, Up 5.7 Percent; GAAP EPS $1.10 - Delivers Fourth-Quarter Adjusted Revenue of $5.371 Billion, Up 8.9 Percent Over Fourth-Quarter 2013 (Up 5.1 Percent On a Reported Basis); GAAP Revenue $5.452 Billion - Revenue Growth in the Quarter Reflects 14.4 Percent
|
|
|
1/16/15
|
AbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call
NORTH CHICAGO, Ill. , Jan. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2014 financial results on Friday, Jan. 30, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.
|
|
|
1/8/15
|
AbbVie Issues Strong Outlook for 2015
- Expects Adjusted Earnings Per Share of $4.25 to $4.45 (GAAP EPS of $3.99 to $4.19); Guidance to be Further Refined as HCV Launch Progresses - Guidance Midpoint Reflects Adjusted EPS Growth of More Than 30 Percent from AbbVie's Previously Communicated 2014 Guidance Range NORTH CHICAGO, Ill. , Jan.
|
|
|
12/30/14
|
AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill. , Dec. 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m.
|
|
|Investors